Abstract
To enhance the potential therapeutic efficacy of an antimicrobial peptide human beta-defensin 3, two fusion peptides, a bactericidal-immunomodulatory fusion peptide human beta-defensin 3-mannose-binding lectin and a bactericidal-bactericidal fusion peptide human beta-defensin 3-lysozyme were synthesized and the bactericidal activities in vitro and in vivo against methicillin-resistant Staphylococcus aureus N315 were demonstrated in this study. Peptide human beta-defensin 3-lysozyme showed the best bactericidal activity in vitro, but human beta-defensin 3-mannose-binding lectin showed a significant improvement in angiogenesis and tissue reconstruction. Our results illustrated that outstanding bactericidal activity in vitro is not essential in the development of antimicrobial peptides. Fusion strategy and immunomodulatory factors should be utilized in novel antimicrobial peptide development.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Amino Acid Sequence
-
Animals
-
Humans
-
Immunologic Factors / chemical synthesis
-
Immunologic Factors / chemistry
-
Immunologic Factors / pharmacology
-
Immunologic Factors / therapeutic use*
-
Male
-
Mannose-Binding Lectin / chemical synthesis
-
Mannose-Binding Lectin / chemistry
-
Mannose-Binding Lectin / pharmacology
-
Mannose-Binding Lectin / therapeutic use*
-
Methicillin-Resistant Staphylococcus aureus / drug effects
-
Mice
-
Mice, Inbred BALB C
-
Microbial Sensitivity Tests
-
Molecular Sequence Data
-
Peptides / chemical synthesis
-
Peptides / chemistry
-
Peptides / pharmacology
-
Peptides / therapeutic use*
-
Recombinant Fusion Proteins / pharmacology
-
Recombinant Fusion Proteins / therapeutic use*
-
Staphylococcal Skin Infections / drug therapy*
-
Staphylococcal Skin Infections / immunology
-
Staphylococcal Skin Infections / microbiology
-
Treatment Outcome
-
Wound Infection / drug therapy
-
Wound Infection / microbiology
-
beta-Defensins / chemical synthesis
-
beta-Defensins / chemistry
-
beta-Defensins / pharmacology
-
beta-Defensins / therapeutic use*
Substances
-
DEFB103A protein, human
-
Immunologic Factors
-
Mannose-Binding Lectin
-
Peptides
-
Recombinant Fusion Proteins
-
beta-Defensins